Compare AbbVie Inc (ABBV) vs Tidewater Inc (TDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Tidewater Inc — how do they compare? AbbVie Inc trades at $248.1 (market cap $441.94B), while Tidewater Inc trades at $91.72 (market cap $4.54B). The key difference: AbbVie Inc is far larger — about 97.3× Tidewater Inc's market cap, and AbbVie Inc pays a 2.77% dividend while Tidewater Inc pays none. Which is the better fit depends on your goals.
| ABBV | TDW | |
|---|---|---|
Market Cap | $441.94B | $4.54B |
Sector | Health | Utilities |
52-Week High | $263.58 | $91.20 |
52-Week Low | $197.38 | $47.29 |
Enterprise Value | $506.19B | $4.58B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $249.9, up 0.8% on the day, with strong analyst support (29 Buy, 1 Sell) and a $278.69 consensus price target. Recent quarterly earnings have consistently beaten estimates, driven by robust immunology drug sales. The stock shows a bullish technical trend, supported by moving averages, and the company maintains solid cash flow and dividend payments.
Outlook is positive with revenue growth and pipeline advancements, though high P/E and debt levels pose risks. The stock offers a compelling buy case for growth and income investors, balanced by execution and patent expiry challenges ahead.
Tidewater (TDW) trades at $91.86, up 2.49% today, with a bullish technical signal from moving averages and ADX indicators. The company reported Q2 2026 earnings of $0.43 per share, beating estimates (Zacks, August 3, 2026), though it missed expectations in prior quarters. Revenue for the quarter was $342.3 million, with net income margins around 18%. Analyst sentiment is mixed, with 26.92% recommending Buy and 57.7% Hold.
Outlook: Strong day rates and utilization support revenue growth, but earnings misses and Middle East operational costs pose risks. The stock's valuation (P/E 18.5) is reasonable, but investors face volatility from oil market exposure and execution challenges. Upside depends on sustained operational improvements and cost management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →
